BIRC3/CAV1 co-expression drives GBM aggressiveness as a prognostic signature and therapeutic vulnerability.

Cell Death Discov · 2026 · PMC13183958 · PMID 41975220

Europe PMC DOI

hedged sentences

—

closest p

—

boldest claim

The sentences

did not reach statistical significanceP = 0.0990so close (0.05 < p ≤ 0.1)

a clear trendno p-value reported

A clear trend in the same direction was observed for Overall Survival (15.99 vs 12.1 months), which approached but did not reach statistical significance ( P = 0.0990; Fig. 4I ), likely reflecting the limited statistical power of this smaller cohort.

also in 19,460 other papers

a strong trendno p-value reported

CAV1 , which was also identified as a key candidate in our previous work, showed a strong trend of upregulation (a 3-fold increase) in the same global analysis, although it narrowly missed the threshold for statistical significance after correction for multiple comparisons ( P adj = 0.0709, Supplementary Data 1 ).

also in 5,725 other papers

an increasing trendno p-value reported

Regarding CASP3 , we observed a divergent pattern: while TMZ treatment significantly reduced CASP3 mRNA levels in sensitive Vector control cells ( P < 0.05), it induced an increasing trend in BIRC3+ and BIRC3 + /CAV1+ resistant cells.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.